← Back to Clinical Trials
Recruiting NCT06388954

NCT06388954 Plasticity Biomarkers,Interleukin-6 and Motor Performance in Response to Vagus Nerve Stimulation After Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06388954
Status Recruiting
Phase
Sponsor Cairo University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-05-28
Primary Completion 2025-01-25

Trial Parameters

Condition Stroke
Sponsor Cairo University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 55 Years
Max Age 65 Years
Start Date 2024-05-28
Completion 2025-01-25
Interventions
True Transcutaneous auricular Vagus Nerve Stimulation (TaVNS)Sham Trancutaneous auricular Vagus Nerve Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Seventy-eight clinically verified Egyptian patients from both sexes with ischemic stroke that occurred at least 6 months to 2 years before inclusion will be randomly assigned into 2 groups, control group (GA) and the experimental group (GB). Patients will be randomly assigned into two equal groups: the control group (GA) and the experimental group (GB). Patients in the control group (GA) will be treated with sham Vagus nerve stimulation (taVNS) immediately before a selected physical therapy program, while in the experimental group (GB), patients will receive real transcutaneous auricular Vagus nerve stimulation (taVNS) followed by the same selected physical therapy program as (GA). Plasma level of Brain-Derived Neurotrophic Factors (BDNF) and Interleukin-6 (IL-6), Box and Blocks Test (BBT), and modified Ashworth scale (MAS) will be assessed at baseline and immediately post-treatment.

Eligibility Criteria

Inclusion Criteria: * Hemiparetic patients with ischemic middle cerebral artery stroke * The duration of illness ranged from at least 6 months to 2 years after stroke. * Patient's age ranged from 55 to 65 years, patients with unilateral upper limb motor function impairment. * Patients able to transfer at least one block in Box and Blocks Test. * Patients with sufficient cognitive abilities that enables them to understand and follow instructions. * Spasticity of upper limb muscles ranged from (grade 1:2) according to Modified Ashworth scale. Exclusion Criteria: * Other neurological diseases that affect upper limb function other than stroke (e.g.: Multiple sclerosis, peripheral neuropathy, Parkinsonism….etc.). * Hemorrhagic stroke * Visual or auditory impairment affecting their ability to complete the testing. * Cognitive impairment. * Cardiovascular problems and pulmonary or kidney disorders * Musculoskeletal disorders (e.g. scoliosis, kyphosis, severe arthritis…etc.) * Severe spasticit

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology